Show simple item record

dc.contributor.authorAhn, Mary S.
dc.contributor.authorSims, Katherine B.
dc.contributor.authorFrazier, Jean A.
dc.date2022-08-11T08:10:27.000
dc.date.accessioned2022-08-23T17:09:37Z
dc.date.available2022-08-23T17:09:37Z
dc.date.issued2005-06-12
dc.date.submitted2011-02-10
dc.identifier.citationJ Child Adolesc Psychopharmacol. 2005 Jun;15(3):520-5. <a href="http://dx.doi.org/10.1089/cap.2005.15.520">Link to article on publisher's site</a>
dc.identifier.issn1044-5463 (Linking)
dc.identifier.doi10.1089/cap.2005.15.520
dc.identifier.pmid16092915
dc.identifier.urihttp://hdl.handle.net/20.500.14038/45865
dc.description.abstractOBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone. DATA: A 16-year-old girl was treated with risperidone for mood lability and impulsivity at a community hospital. Within days, she developed paranoid ideation, profound psychomotor retardation, increased depression, and fatigue. She was transferred to an inpatient psychiatric hospital, where she was taken off risperidone. Within 48 hours after discontinuation of the medication, she had complete resolution of psychotic symptoms, fatigue, and psychomotor retardation, and her depression improved. CONCLUSIONS: This observation of "on-off" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent. These findings are consistent with recent in vitro literature, which implicate a series of neuroleptic medications with mitochondrial dysfunction. Furthermore, the authors provide diagnostic and treatment options that are available for mitochondrial disorders, which are of interest to child psychiatrists due to the central nervous system manifestations of these disorders.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=16092915&dopt=Abstract">Link to Article in PubMed</a>
dc.rightsThis is a copy of an article published in the Journal of Child and Adolescent Psychopharmacology. © 2005 Mary Ann Liebert, Inc.
dc.subjectAdolescent
dc.subjectDepressive Disorder
dc.subjectEpilepsy, Tonic-Clonic
dc.subjectFemale
dc.subjectHumans
dc.subjectMitochondrial Diseases
dc.subjectMood Disorders
dc.subjectPsychoses, Substance-Induced
dc.subjectRisperidone
dc.subjectPsychiatry
dc.titleRisperidone-induced psychosis and depression in a child with a mitochondrial disorder
dc.typeJournal Article
dc.source.journaltitleJournal of child and adolescent psychopharmacology
dc.source.volume15
dc.source.issue3
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1394&amp;context=psych_pp&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/psych_pp/395
dc.identifier.contextkey1775330
refterms.dateFOA2022-08-23T17:09:37Z
html.description.abstract<p>OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.</p> <p>DATA: A 16-year-old girl was treated with risperidone for mood lability and impulsivity at a community hospital. Within days, she developed paranoid ideation, profound psychomotor retardation, increased depression, and fatigue. She was transferred to an inpatient psychiatric hospital, where she was taken off risperidone. Within 48 hours after discontinuation of the medication, she had complete resolution of psychotic symptoms, fatigue, and psychomotor retardation, and her depression improved.</p> <p>CONCLUSIONS: This observation of "on-off" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent. These findings are consistent with recent in vitro literature, which implicate a series of neuroleptic medications with mitochondrial dysfunction. Furthermore, the authors provide diagnostic and treatment options that are available for mitochondrial disorders, which are of interest to child psychiatrists due to the central nervous system manifestations of these disorders.</p>
dc.identifier.submissionpathpsych_pp/395
dc.contributor.departmentDepartment of Psychiatry
dc.source.pages520-5


Files in this item

Thumbnail
Name:
JCAP_2005_risperidone_induced_ ...
Size:
62.06Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record